CD274 and cancer: These agents remove the immunosuppressive “brakes” imposed by cancer cells on the immune system, such as the PD-1/PD-L1 pathway, thereby unleashing the full potential of immune cells like T cells to recognize and attack cancer cells more efficiently.308,309 Notably, the PD-1/PD-L1 pathway serves as a pivotal immune regulatory axis, with drugs such as pembrolizumab and nivolumab targeting PD-1.